Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Singh, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 749-755
© 2000 The British Society for Antimicrobial Chemotherapy

Review

Invasive mycoses in organ transplant recipients: controversies in prophylaxis and management

Nina Singh*

VA Medical Center and University of Pittsburgh Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, USA


   Introduction
 
Organ transplant recipients are a growing and increasingly important group of immunocompromised hosts in whom invasive mycoses remain one of the most significant infectious complications.1–3 Although candida infections occur more frequently, the highest mortality rate associated with fungal infections in transplant recipients is for Aspergillus spp. infections.4 The last decade has witnessed the emergence of diverse mycelial fungi, including dematiaceous moulds, as significant pathogens in transplant patients.5 Trends in invasive fungal infections in the post-transplant setting have also been notable for a rise in non-albicans Candida spp.6

Given the high mortality associated with invasive mycoses in transplant recipients, effective prophylaxis for such infections is a worthy goal: an optimal approach has not, however, been devised. Uncertainty and controversy abound regarding the choice of antifungal agent, mode of drug delivery and types of patients who should receive antifungal prophylaxis. The lipid formulations of amphotericin B represent a significant advance in . . . [Full Text of this Article]


   Antifungal prophylaxis
 

   Antifungal therapy
 

   Adjunctive therapies
 
Role of surgery

Immunomodulatory therapies


   Notes
 

   References
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
N. Singh and D. L. Paterson
Aspergillus Infections in Transplant Recipients
Clin. Microbiol. Rev., January 1, 2005; 18(1): 44 - 69.
[Abstract] [Full Text] [PDF]